Omada Health, Inc.

Omada Health reported strong financial results for the second quarter and first half of 2026, marking a significant turnaround from the previous year. The company achieved a net income of $5.3 million in Q2 2026, reversing a net loss of $5.3 million in Q2 2025, driven by a 43.1% increase in total revenue to $87.8 million. For the six months ended June 30, 2026, Omada Health also posted a net income of $2.3 million, compared to a net loss of $14.8 million in the prior year period, with total revenue reaching $165.9 million.

Omada Health announced a leadership transition, with President Wei-Li Shao succeeding co-founder Sean Duffy as CEO, effective January 1, 2027. Mr. Duffy will transition to Executive Chair, and Jeryl Hilleman will become Lead Independent Director. Concurrently, the company reported strong second-quarter 2026 financial results, with revenue growing 43% to $88 million and achieving a net income of $5 million, a significant improvement from a net loss in the prior year. Omada Health also raised its full-year 2026 revenue and Adjusted EBITDA guidance, reflecting continued operational momentum and profitability.

Omada Health announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will host a conference call and webcast on the same day at 4:30 pm ET to discuss the results. A live audio webcast will be available on the company's investor relations website, with a replay accessible for approximately 12 months.

Omada Health, a virtual healthcare provider, announced it will host its inaugural Investor Day on Thursday, September 10, 2026. The half-day, in-person event will take place in New York City, starting at 1:00 pm EDT. Senior management will present the company's vision, strategy, and long-term growth plans to investors. A live webcast and replay will be accessible via the company's investor relations website.

Omada Health announced that its senior management will participate in Canaccord Genuity's 46th annual Growth Conference in Boston. The event will include a fireside chat on Tuesday, August 11, at 8:00 a.m. EDT. A live webcast and replay will be accessible through the company's investor relations website.

Omada Health reported a strong first quarter for 2026, with total revenue increasing by 42% to $78.0 million. The company significantly narrowed its net loss to $3.0 million, or $0.05 per share, compared to a $9.4 million loss in the prior year. This performance reflects robust growth across both service and hardware segments, alongside improved operating efficiency and reduced cash usage in operations.

Omada Health announced a partnership with Eli Lilly and Company's Employer Connect program, enabling Omada to offer its GLP-1 Care Track directly to employers. This collaboration provides a new channel for employers to offer weight loss medications like Zepbound with coordinated lifestyle support, alongside Omada's existing pharmacy benefit manager and cash-pay pathways. The initiative aims to address the growing demand for anti-obesity medicines and the challenges employers face in providing consistent coverage, offering transparent costs and predictable structures. Omada's recent survey highlighted significant gaps in patient support and access, with many desiring more guidance and facing high out-of-pocket costs, which Omada's program seeks to bridge.

Omada Health reported strong first-quarter 2026 financial results, with revenue increasing 42% year over year to $78 million and total members surpassing one million, up 51% year over year. The company achieved positive Adjusted EBITDA of $1 million, a significant improvement from a $4 million loss in the prior year. Omada also expanded its channel partnerships to include all three leading PBMs, notably joining Optum Rx’s Weight Engage portfolio and Eli Lilly’s Employer Connect program, and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Omada Health, Inc. announced its 2026 Annual Meeting of Stockholders will take place virtually on June 16, 2026. Stockholders will vote on the re-election of two Class I Directors, Sean Duffy and Trevor Fetter, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for voting was April 20, 2026.

Omada Health announced new study results for its GLP-1 Care Track, showing significant improvements for members. Participants in the program lost 1.8 times more total weight and reduced body fat percentage twice as much as a comparison group. The study also indicated an increase in muscle mass percentage and improved well-being measures, suggesting Omada's program optimizes GLP-1 weight loss while mitigating muscle loss risks.